查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797997

2032 年胚胎胚胎著床前基因檢測市場預測：按產品、流程、技術、應用、最終用戶和地區進行的全球分析

Preimplantation Genetic Testing Market Forecasts to 2032 - Global Analysis By Product (Reagents & Consumables, Instruments and Software), Procedure, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球胚胎著床前基因檢測市場預計在 2025 年達到 8.831 億美元，到 2032 年將達到 21.033 億美元，預測期內的複合年成長率為 13.2%。

胚胎著床前基因檢測是對透過體外受精 (IVF) 產生的胚胎進行的程序，用於在受孕前識別基因或染色體異常。該程序涉及分析胚胎中的一個或多個細胞，以篩檢遺傳疾病、染色體正常性或其他遺傳疾病。這項檢測有助於選擇健康的胚胎進行植入，從而降低後代遺傳疾病的風險。

根據美國衛生與公眾服務部的數據，數百萬美國人在一生中的某個階段都會受到不孕症的影響。試管嬰兒（IVF）是治療不孕症的關鍵方法，佔人工授精的99%以上。

遺傳疾病和不孕症增多

全球遺傳性疾病和不孕症盛行率的上升是胚胎胚胎著床前基因檢測市場的主要驅動力。選擇輔助生殖技術的夫妻擴大尋求基因篩檢，以降低胚胎中遺傳性疾病的風險。診斷準確性的提高以及對染色體異常認知的提高進一步推動了這一需求。隨著母親年齡的成長和不孕症的上升，尤其是在都市區，胚胎植入前基因檢測 (PGT) 已成為確保健康懷孕的主動解決方案。

高成本且報銷政策有限

儘管胚胎胚胎著床前基因檢測 (PGT) 具有臨床益處，但高成本仍然是其發展的一大障礙，尤其是在新興經濟體。有限的保險覆蓋範圍和嚴格的報銷政策阻礙了其廣泛應用。許多患者面臨高昂的自付費用，尤其是在PGT與IVF捆綁治療的情況下。此外，法律規範的地區差異進一步限制了PGT的可及性。這些經濟和政策限制阻礙了市場滲透，尤其是在中等收入者和公共醫療體系中。

體外受精和輔助生殖技術的採用日益增多

體外受精 (IVF) 和其他輔助生殖技術 (ART) 的廣泛應用為 PGT 市場創造了巨大的成長機會。隨著 IVF 成功率的提高，越來越多的診所開始整合基因檢測，以提高植入成功率並降低流產率。 ART 在同性伴侶、單親家庭以及反覆流產人群中越來越受歡迎，擴大了其患者群體。人工智慧 (AI) 與次世代定序(NGS) 的整合進一步提高了 PGT 的準確性，吸引了新的人群，並推動了臨床成功。

某些人群缺乏意識

人們對胚胎胚胎著床前基因檢測 (PGT) 的認知不足，對市場擴張構成了重大威脅，尤其是在農村和低度開發地區。儘管不孕症盛行率不斷上升，但誤解、社會文化禁忌以及有限的遺傳素養仍導致該技術普及率低。此外，患者和醫療保健提供者缺乏關於 PGT 益處和合格標準的教育，阻礙了早期應用。這種認知差距持續延誤了及時干預，尤其是在高風險遺傳性疾病帶原者中，從而限制了市場潛力的充分發揮。

COVID-19的影響：

新冠疫情擾亂了全球生育服務，導致體外受精（IVF）延期，PGT（胚胎植入前基因檢測）服務量暫時下降。診所面臨人員短缺、出行限制以及試劑和檢測套組供應鏈中斷等問題。然而，疫情過後，生育治療逐漸復甦，人們對基因健康的關注也隨之上升。遠端醫療、數位化問診和遠距遺傳諮詢恢復了患者的參與度，在醫療保健數位化不斷提升的背景下，支持PGT服務的再度成長。

試劑和耗材部分預計將成為預測期內最大的部分

由於每個檢查週期的需求反覆出現，預計試劑和耗材細分市場將在預測期內佔據最大市場佔有率。實驗室依賴高品質的試劑、探針和套件進行準確的胚胎分析，推動了持續的消費。分子診斷工具和基於NGS的檢測的不斷進步也增加了對專用試劑的需求。此外，全球試管嬰兒（IVF）手術數量的不斷增加使得耗材的定期採購成為必要，這使得該細分市場成為診斷供應商的主要收益驅動力。

預計胚胎著床前基因篩檢領域在預測期內將出現最高的複合年成長率

預計在預測期內，胚胎著床前遺傳學篩檢(PGS) 細分市場將呈現最高成長率，這得益於人們對提高體外受精 (IVF) 成功率和預防染色體異常日益成長的需求。 PGS 有助於識別非整倍體和結構重排，從而篩選出具有遺傳學可行性的胚胎。隨著母親年齡的成長，尤其是在已開發國家，PGS 的重要性日益凸顯。此外，NGS 與自動化分析的整合正在提高篩檢通訊協定的效率、準確性和可近性。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於不孕症治療旅遊的擴張、不孕症的上升以及輔助生殖技術（ART）應用的日益普及。在醫療基礎設施的改善和扶持政策的支持下，印度、中國和日本等國家正經歷先進生殖健康服務的激增。此外，日益成長的醫療旅遊業和具有競爭力的治療費用也吸引了許多外國患者。該地區龐大的育齡人口和日益成長的遺傳健康意識，正幫助其在市場上佔據主導地位。

複合年成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率。這得益於其先進的醫療基礎設施、較高的輔助生殖技術 (ART) 普及率以及部分州的優惠報銷政策。對個人化生殖解決方案和老年父母早期篩檢的強勁需求，推動了胚胎植入前基因檢測 (PGT) 的普及。此外，領先的基因組檢測公司、清晰的監管體係以及胚胎診斷領域的持續臨床創新，也支撐著市場的快速擴張。提升患者意識提升和不孕症教育的舉措也推動了該地區的成長動能。

免費客製化服務

訂閱此報告的用戶可獲得以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球胚胎著床前基因檢測市場（按產品）

  • 試劑和耗材
  • 裝置
  • 軟體

6. 全球胚胎著床前基因檢測市場（依程序）

  • 胚胎胚胎著床前基因篩檢
  • 胚胎著床前基因診斷

7. 全球胚胎著床前基因檢測市場（依技術）

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 螢光原位雜合技術（FISH）
  • 其他技術

8. 全球胚胎胚胎著床前基因檢測市場（依應用）

  • 染色體異常
  • X連鎖疾病
  • 胚胎偵測
  • 非整倍體篩檢
  • HLA型檢測
  • 其他用途

9. 全球胚胎著床前基因檢測市場（依最終用戶）

  • 不孕不孕治療中心
  • 醫院
  • 診斷中心
  • 研究中心和學術研究機構

第10章全球胚胎著床前基因檢測市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer, Inc.
  • CooperSurgical
  • Abbott Laboratories
  • Natera
  • Rubicon Genomics
  • Oxford Gene Technology
  • Yikon Genomics
  • Good Start Genetics
  • Invicta Genetics
  • Progenesis
  • Igenomix
  • Bioarray SL
  • Quest Diagnostics
  • Fulgent Genetics, Inc.
  • Labcorp
  • Genea Limited
Product Code: SMRC30367

According to Stratistics MRC, the Global Preimplantation Genetic Testing Market is accounted for $883.1 million in 2025 and is expected to reach $2103.3 million by 2032 growing at a CAGR of 13.2% during the forecast period. Preimplantation genetic testing is a laboratory procedure performed on embryos created via in vitro fertilization (IVF) to identify genetic or chromosomal abnormalities before pregnancy. It involves analyzing one or more cells from the embryo to screen for inherited diseases, chromosomal normality, or other genetic conditions. This testing helps select healthy embryos for implantation, reducing the risk of genetic disorders in the offspring.

According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures.

Market Dynamics:

Driver:

Increasing incidence of genetic disorders and infertility

The rising global prevalence of genetic disorders and infertility is a primary driver for the preimplantation genetic testing market. Couples opting for assisted reproductive technologies increasingly seek genetic screening to reduce the risk of inherited conditions in embryos. Advancements in diagnostic accuracy and awareness of chromosomal abnormalities have further spurred demand. With maternal age on the rise and infertility rates escalating, particularly in urban populations, PGT is emerging as a proactive solution to ensure healthy pregnancies.

Restraint:

High cost and limited reimbursement policies

Despite its clinical benefits, the high cost of preimplantation genetic testing remains a significant barrier, especially in developing economies. Limited insurance coverage and restrictive reimbursement policies discourage widespread adoption. Many patients are burdened with out-of-pocket expenses, particularly when PGT is bundled with in-vitro fertilization. Moreover, variability in regulatory frameworks across regions further constrains access. These financial and policy constraints hinder market penetration, particularly among middle-income demographics and public healthcare systems.

Opportunity:

Growing adoption of IVF and assisted reproductive technologies

Widespread adoption of in-vitro fertilization (IVF) and other assisted reproductive technologies (ART) presents a strong growth opportunity for the PGT market. As success rates of IVF improve, clinics increasingly integrate genetic testing to enhance implantation outcomes and reduce miscarriages. Rising acceptance of ART among same-sex couples, single parents, and those with recurrent pregnancy loss has broadened the patient base. The integration of AI and next-generation sequencing (NGS) further enhances PGT accuracy, attracting newer demographics and boosting clinical success.

Threat:

Lack of awareness in certain populations

Inadequate awareness regarding preimplantation genetic testing, particularly in rural and underdeveloped regions, poses a critical threat to market expansion. Misconceptions, socio-cultural taboos, and limited genetic literacy reduce adoption rates despite increasing infertility cases. Additionally, lack of education among patients and healthcare providers about the benefits and eligibility criteria of PGT hinders early consultation. This awareness gap continues to delay timely intervention, particularly among high-risk carriers of genetic diseases, curbing the market's full potential.

Covid-19 Impact:

The COVID-19 pandemic disrupted fertility services globally, leading to postponed IVF cycles and a temporary decline in PGT procedures. Clinics faced staff shortages, mobility restrictions, and supply chain interruptions for reagents and test kits. However, post-pandemic recovery has been marked by a rebound in fertility treatments and increased emphasis on genetic health. Telemedicine, digitized consultations, and remote genetic counseling have helped restore patient engagement, supporting renewed growth in PGT services amid strengthened healthcare digitization.

The reagents & consumables segment is expected to be the largest during the forecast period

The reagents & consumables segment is expected to account for the largest market share during the forecast period, due to its recurring demand across every testing cycle. Laboratories rely on high-quality reagents, probes, and kits for accurate embryo analysis, driving consistent consumption. Continuous advancements in molecular diagnostic tools and NGS-based testing have also increased demand for specialized reagents. Additionally, the growing volume of IVF procedures globally necessitates regular procurement of consumables, making this segment a critical revenue driver for diagnostic suppliers.

The preimplantation genetic screening segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the preimplantation genetic screening segment is predicted to witness the highest growth rate, impelled by the growing desire to improve IVF success rates and prevent chromosomal abnormalities. PGS aids in identifying aneuploidy and structural rearrangements, enabling the selection of genetically viable embryos. As maternal age rises, especially in developed nations, the relevance of PGS continues to grow. Additionally, the integration of NGS and automated analytics is enhancing efficiency, accuracy, and accessibility of screening protocols.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding fertility tourism, rising infertility rates, and increased ART adoption. Countries like India, China, and Japan are witnessing a surge in advanced reproductive services, backed by improving healthcare infrastructure and supportive policies. In addition, growing medical tourism and competitive treatment costs attract international patients. The region's large reproductive-age population and rising awareness around genetic health contribute to its dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high adoption of ART, and favorable reimbursement scenarios in select states. Strong demand for personalized reproductive solutions and early screening among older parents bolsters PGT uptake. Furthermore, the presence of leading genomic testing firms, regulatory clarity, and ongoing clinical innovations in embryo diagnostics support rapid market expansion. Patient awareness and fertility education initiatives also enhance regional growth momentum.

Key players in the market

Some of the key players in Preimplantation Genetic Testing Market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Good Start Genetics, Invicta Genetics, Progenesis, Igenomix, Bioarray S.L., Quest Diagnostics, Fulgent Genetics, Inc., Labcorp, and Genea Limited.

Key Developments:

In February 2025, Thermo Fisher Scientific expanded its PGT capabilities with an integrated NGS workflow allowing a single sample to be assessed for both PGT-A (aneuploidy) and PGT-M (monogenic disorders) using Ion Torrent technology-offering comprehensive results with rapid turnaround and accessible analysis tools.

In January 2025, Illumina launched major upgrades to its NovaSeq X Series, including a new single-flow-cell system, advanced software, and improved reagent kits, further strengthening its leadership in genomic sequencing, a key technology for PGT.

Products Covered:

  • Reagents & Consumables
  • Instruments
  • Software

Procedures Covered:

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Technologies Covered:

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Other Technologies

Applications Covered:

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other Applications

End Users Covered:

  • Fertility Centers
  • Hospitals
  • Diagnostic Centers
  • Research Centers & Academic Labs

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preimplantation Genetic Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents & Consumables
  • 5.3 Instruments
  • 5.4 Software

6 Global Preimplantation Genetic Testing Market, By Procedure

  • 6.1 Introduction
  • 6.2 Preimplantation Genetic Screening
  • 6.3 Preimplantation Genetic Diagnosis

7 Global Preimplantation Genetic Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Next Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Fluorescent In-Situ Hybridization (FISH)
  • 7.5 Other Technologies

8 Global Preimplantation Genetic Testing Market, By Application

  • 8.1 Introduction
  • 8.2 Chromosomal Abnormalities
  • 8.3 X-linked Diseases
  • 8.4 Embryo Testing
  • 8.5 Aneuploidy Screening
  • 8.6 HLA Typing
  • 8.7 Other Applications

9 Global Preimplantation Genetic Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Fertility Centers
  • 9.3 Hospitals
  • 9.4 Diagnostic Centers
  • 9.5 Research Centers & Academic Labs

10 Global Preimplantation Genetic Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Illumina, Inc.
  • 12.2 Thermo Fisher Scientific, Inc.
  • 12.3 Agilent Technologies, Inc.
  • 12.4 PerkinElmer, Inc.
  • 12.5 CooperSurgical
  • 12.6 Abbott Laboratories
  • 12.7 Natera
  • 12.8 Rubicon Genomics
  • 12.9 Oxford Gene Technology
  • 12.10 Yikon Genomics
  • 12.11 Good Start Genetics
  • 12.12 Invicta Genetics
  • 12.13 Progenesis
  • 12.14 Igenomix
  • 12.15 Bioarray S.L.
  • 12.16 Quest Diagnostics
  • 12.17 Fulgent Genetics, Inc.
  • 12.18 Labcorp
  • 12.19 Genea Limited

List of Tables

  • Table 1 Global Preimplantation Genetic Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Preimplantation Genetic Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Preimplantation Genetic Testing Market Outlook, By Reagents & Consumables (2024-2032) ($MN)
  • Table 4 Global Preimplantation Genetic Testing Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 5 Global Preimplantation Genetic Testing Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Preimplantation Genetic Testing Market Outlook, By Procedure (2024-2032) ($MN)
  • Table 7 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Screening (2024-2032) ($MN)
  • Table 8 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Diagnosis (2024-2032) ($MN)
  • Table 9 Global Preimplantation Genetic Testing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global Preimplantation Genetic Testing Market Outlook, By Next Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 11 Global Preimplantation Genetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 12 Global Preimplantation Genetic Testing Market Outlook, By Fluorescent In-Situ Hybridization (FISH) (2024-2032) ($MN)
  • Table 13 Global Preimplantation Genetic Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 14 Global Preimplantation Genetic Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 15 Global Preimplantation Genetic Testing Market Outlook, By Chromosomal Abnormalities (2024-2032) ($MN)
  • Table 16 Global Preimplantation Genetic Testing Market Outlook, By X-linked Diseases (2024-2032) ($MN)
  • Table 17 Global Preimplantation Genetic Testing Market Outlook, By Embryo Testing (2024-2032) ($MN)
  • Table 18 Global Preimplantation Genetic Testing Market Outlook, By Aneuploidy Screening (2024-2032) ($MN)
  • Table 19 Global Preimplantation Genetic Testing Market Outlook, By HLA Typing (2024-2032) ($MN)
  • Table 20 Global Preimplantation Genetic Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 21 Global Preimplantation Genetic Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Preimplantation Genetic Testing Market Outlook, By Fertility Centers (2024-2032) ($MN)
  • Table 23 Global Preimplantation Genetic Testing Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global Preimplantation Genetic Testing Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 25 Global Preimplantation Genetic Testing Market Outlook, By Research Centers & Academic Labs (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.